CN1313079C - Traditional Chinese medicine preparation for treating prostatitis and preparation method thereof - Google Patents
Traditional Chinese medicine preparation for treating prostatitis and preparation method thereof Download PDFInfo
- Publication number
- CN1313079C CN1313079C CNB2005100546933A CN200510054693A CN1313079C CN 1313079 C CN1313079 C CN 1313079C CN B2005100546933 A CNB2005100546933 A CN B2005100546933A CN 200510054693 A CN200510054693 A CN 200510054693A CN 1313079 C CN1313079 C CN 1313079C
- Authority
- CN
- China
- Prior art keywords
- fine powder
- bee pollen
- anemarrhena
- water
- rapeseed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 37
- 239000003814 drug Substances 0.000 title claims abstract description 27
- 201000007094 prostatitis Diseases 0.000 title claims abstract description 16
- 229940038481 bee pollen Drugs 0.000 claims abstract description 42
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 30
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 30
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims abstract description 22
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims abstract description 22
- 239000000843 powder Substances 0.000 claims description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- 240000002791 Brassica napus Species 0.000 claims description 29
- 235000004977 Brassica sinapistrum Nutrition 0.000 claims description 29
- 241000207925 Leonurus Species 0.000 claims description 26
- 241000605447 Anemarrhena Species 0.000 claims description 23
- 239000000284 extract Substances 0.000 claims description 23
- 239000008187 granular material Substances 0.000 claims description 16
- 229930191283 anemarrhena Natural products 0.000 claims description 15
- 239000002775 capsule Substances 0.000 claims description 14
- 239000006187 pill Substances 0.000 claims description 14
- 241000972672 Phellodendron Species 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 229920002472 Starch Polymers 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 235000012907 honey Nutrition 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000002002 slurry Substances 0.000 claims description 4
- -1 dry Substances 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 239000007888 film coating Substances 0.000 claims description 3
- 238000009501 film coating Methods 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 239000007779 soft material Substances 0.000 claims description 3
- 235000020985 whole grains Nutrition 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 abstract description 12
- 210000002307 prostate Anatomy 0.000 abstract description 3
- 230000007012 clinical effect Effects 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 208000017667 Chronic Disease Diseases 0.000 abstract 1
- 240000007890 Leonurus cardiaca Species 0.000 abstract 1
- 241000972673 Phellodendron amurense Species 0.000 abstract 1
- PZZRDJXEMZMZFD-ODPGBAFUSA-N Reynoutrin Natural products O[C@H]1[C@H](O)[C@@H](O)CO[C@@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O PZZRDJXEMZMZFD-ODPGBAFUSA-N 0.000 abstract 1
- BDCDNTVZSILEOY-UXYNSRGZSA-N avicularin Chemical compound O[C@@H]1[C@@H](O)[C@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O BDCDNTVZSILEOY-UXYNSRGZSA-N 0.000 abstract 1
- QIARVOTYSDZZQL-UHFFFAOYSA-N avicularin Natural products OCC1OC(Oc2cc(O)c3C(=O)C(=C(Oc3c2)c4ccc(O)c(O)c4)O)C(O)C1O QIARVOTYSDZZQL-UHFFFAOYSA-N 0.000 abstract 1
- ALRFYJWUVHBXLV-UHFFFAOYSA-N guaijaverin Natural products OC1COC(COC2=C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O ALRFYJWUVHBXLV-UHFFFAOYSA-N 0.000 abstract 1
- BDCDNTVZSILEOY-UHFFFAOYSA-N polystachoside Natural products OC1C(O)C(CO)OC1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O BDCDNTVZSILEOY-UHFFFAOYSA-N 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 20
- 230000000694 effects Effects 0.000 description 16
- 239000000047 product Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 235000002020 sage Nutrition 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 239000013256 coordination polymer Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000013558 reference substance Substances 0.000 description 5
- 210000001635 urinary tract Anatomy 0.000 description 5
- DUNMULOWUUIQIL-RGMNGODLSA-N (2s)-1,1-dimethylpyrrolidin-1-ium-2-carboxylic acid;chloride Chemical compound Cl.C[N+]1(C)CCC[C@H]1C([O-])=O DUNMULOWUUIQIL-RGMNGODLSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 208000013507 chronic prostatitis Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000001850 reproductive effect Effects 0.000 description 4
- 230000001568 sexual effect Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000007799 cork Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000035784 germination Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 1
- 241001282315 Nemesis Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000025844 Prostatic disease Diseases 0.000 description 1
- 206010041956 Stasis syndrome Diseases 0.000 description 1
- MHLMRBVCMNDOCW-UHFFFAOYSA-N acetic acid;butan-1-ol;hydrate Chemical compound O.CC(O)=O.CCCCO MHLMRBVCMNDOCW-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 208000005634 blind loop syndrome Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- FDRNFGFHVYOUDO-UHFFFAOYSA-M potassium N,N-diethylethanamine dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O.CCN(CC)CC FDRNFGFHVYOUDO-UHFFFAOYSA-M 0.000 description 1
- XYKIUTSFQGXHOW-UHFFFAOYSA-N propan-2-one;toluene Chemical compound CC(C)=O.CC1=CC=CC=C1 XYKIUTSFQGXHOW-UHFFFAOYSA-N 0.000 description 1
- NHDHVHZZCFYRSB-UHFFFAOYSA-N pyriproxyfen Chemical compound C=1C=CC=NC=1OC(C)COC(C=C1)=CC=C1OC1=CC=CC=C1 NHDHVHZZCFYRSB-UHFFFAOYSA-N 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000011003 system suitability test Methods 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
技术领域:本发明涉及一种治疗前列腺炎的中药制剂及其制备工艺,属于中药技术的领域。Technical field: The present invention relates to a kind of traditional Chinese medicine preparation for treating prostatitis and its preparation process, which belongs to the field of traditional Chinese medicine technology.
技术背景:慢性前列腺炎是男性的常见病和多发病。具有病种多、发病率高、发病的年长的特点,据国内统计资料,其发病率在成年男子中占35%~40%,且有逐年增多的趋势,给工作、生活、学习造成许多不便。目前在治疗慢性前列腺炎的药物选择很多,但疗效均不甚理想,且复发率较高。Technical background: Chronic prostatitis is a common and frequently-occurring disease of men. It has the characteristics of many types of diseases, high incidence rate, and older age. According to domestic statistics, its incidence rate accounts for 35% to 40% in adult men, and it has a tendency to increase year by year, causing many problems for work, life, and study. inconvenient. At present, there are many drug options for the treatment of chronic prostatitis, but the curative effect is not satisfactory, and the recurrence rate is high.
发明内容:本发明的目的在于:提供一种治疗前列腺炎的中药制剂及其制备工艺,这种制剂具有清热利湿,活血散结的功能,能够有效治疗慢性前列腺炎;效果比较明显,治疗成本低廉;制备方法工艺简单、药品质量控制方便、严格;本发明是这样构成的:治疗前列腺炎的中药制剂:按照重量组分计算,它由益母草187.5-1500、萹蓄125-1000、红花62.5-500、油菜蜂花粉25-200、知母37.5-300和黄柏37.5-300制备而成。具体的说:按照重量计算,它由益母草750g、萹蓄500g、红花250g、油菜蜂花粉100g、盐炒知母150g和盐炒黄柏150g制备而成。所述制剂为所有医学上允许的制剂,包括口服制剂,如:片剂、胶囊剂、软胶囊剂、颗粒剂、口服液体制剂、滴丸剂、丸剂、酒剂、酊剂、浸膏剂;注射制剂,包括:普通针剂、粉针剂、冻干粉针剂、输液剂;其他特殊制剂,包括缓控释制剂、贴膜剂、凝胶剂。Summary of the invention: The object of the present invention is to provide a traditional Chinese medicine preparation for treating prostatitis and its preparation process. This preparation has the functions of clearing away heat and promoting dampness, promoting blood circulation and dispelling stagnation, and can effectively treat chronic prostatitis; the effect is relatively obvious, and the treatment cost Inexpensive; the preparation method process is simple, the medicine quality control is convenient, strict; the present invention is constituted like this: the traditional Chinese medicine preparation for the treatment of prostatitis: calculate according to weight component, it is made up of motherwort 187.5-1500, safflower 125-1000, safflower 62.5 -500, rapeseed bee pollen 25-200, Anemarrhena 37.5-300 and Phellodendron 37.5-300. Specifically: Calculated by weight, it is prepared from 750g of motherwort, 500g of safflower, 250g of safflower, 100g of rapeseed bee pollen, 150g of salt-fried anemarrhena and 150g of salt-fried phellodendron. The preparations are all medically permitted preparations, including oral preparations, such as: tablets, capsules, soft capsules, granules, oral liquid preparations, dripping pills, pills, wine preparations, tinctures, extracts; injection preparations, Including: ordinary injections, powder injections, freeze-dried powder injections, infusions; other special preparations, including sustained and controlled release preparations, film preparations, and gels.
治疗前列腺炎的中药制剂的制备工艺:按照重量组分称取益母草187.5-1500、萹蓄125-1000、红花62.5-500、油菜蜂花粉25-200、知母37.5-300、黄柏37.5-300,取油菜蜂花粉破壁后用高速粉碎机粉碎成80目以上的细粉;其余益母草、萹蓄、红花、知母、黄柏分别加5-20倍量水煎煮1-5次,每次1-5小时,粗滤、1000~10000rpm离心,合并离心后所得水液,减压浓缩成浸膏,减压干燥;干浸膏粉碎成80目以上的细粉,加入油菜蜂花粉细粉,再用不同的方法可以制成不同的制剂。The preparation process of the traditional Chinese medicine preparation for treating prostatitis: according to the weight components, take 187.5-1500 motherwort, 125-1000 safflower, 62.5-500 safflower, 25-200 rape bee pollen, 37.5-300 anemarrhena, and 37.5-300 cork phellodendri 1. Take rapeseed bee pollen and break the wall and use a high-speed pulverizer to crush it into a fine powder of more than 80 mesh; add 5-20 times the amount of water to decoct the remaining motherwort, sage, safflower, Anemarrhena, and Phellodendron 1-5 times, each time 1-5 hours, coarse filtration, 1000~10000rpm centrifugation, combined centrifuged obtained water liquid, concentrated under reduced pressure to form extract, dried under reduced pressure; dry extract was crushed into fine powder above 80 mesh, and rape bee pollen fine powder was added , and then different preparations can be made by different methods.
胶囊剂这样制备:取油菜蜂花粉破壁后用高速粉碎机粉碎成120目的细粉。其余益母草、萹蓄、红花、知母、黄柏分别加水煎煮2次,每次2小时,第一次加12倍量水,第二次加10倍量水,合并水煎液,减压浓缩成50℃时测相对密度为1.33~1.37浸膏,干燥;干浸膏粉碎成80目以上的细粉,加入油菜蜂花粉细粉、淀粉混合均匀,用浓度为85%乙醇制粒,干燥,整粒,充填,即得胶囊。The capsules are prepared in the following way: the rapeseed bee pollen is broken and crushed into 120-mesh fine powder with a high-speed pulverizer. The remaining motherwort, sage, safflower, anemarrhena, and Phellodendron cork were decocted twice, each time for 2 hours, adding 12 times the amount of water for the first time, adding 10 times the amount of water for the second time, combining the decoction, and decompressing. When concentrated to 50°C, the measured relative density is 1.33-1.37. The extract is dried; the dry extract is crushed into a fine powder of 80 mesh or more, added with rape bee pollen fine powder and starch, mixed evenly, granulated with 85% ethanol, and dried. , the whole grain, filling, that is, capsules.
片剂这样制备:取油菜蜂花粉破壁后用高速粉碎机粉碎成80目的细粉。其余益母草、萹蓄、红花、知母、黄柏分别加5倍量水煎煮5次,每次5小时,合并水煎液,减压浓缩成浸膏,减压干燥;干浸膏粉碎成80目的细粉,加入油菜蜂花粉细粉、硬脂酸镁混合均匀,用浓度为75%乙醇制粒,压片,用薄膜包衣辅料对素片进行包衣,即得片剂。Tablets are prepared in the following way: take rapeseed bee pollen and break the wall and crush it into 80-mesh fine powder with a high-speed pulverizer. The remaining motherwort, succulents, safflower, anemarrhena, and cortex were decocted with 5 times the amount of water for 5 times, 5 hours each time, combined with decoction, concentrated under reduced pressure to obtain extract, and dried under reduced pressure; the dry extract was crushed into The 80-mesh fine powder is added with rapeseed bee pollen fine powder and magnesium stearate, mixed evenly, granulated with 75% ethanol, compressed into tablets, and coated with film coating auxiliary materials to obtain tablets.
颗粒剂这样制备:取油菜蜂花粉破壁后用高速粉碎机粉碎成80目的细粉。其余益母草、萹蓄、红花、知母、黄柏分别加10倍量水煎煮1小时,1000rpm离心,离心后所得水液减压浓缩成浸膏,减压干燥;干浸膏粉碎成80目的细粉,加入油菜蜂花粉,浓度为10%的淀粉浆混合均匀后制成软材,过筛,制颗粒,干燥,整粒,即得颗粒剂。The granules are prepared in the following way: the rapeseed bee pollen is broken and crushed into 80-mesh fine powder with a high-speed pulverizer. Add 10 times the amount of water to decoct the remaining motherwort, sage, safflower, Anemarrhena anemarrhena, and Cortex Phellodendri respectively for 1 hour, and centrifuge at 1000 rpm. For the fine powder, add rapeseed bee pollen and starch slurry with a concentration of 10% and mix evenly to make a soft material, sieve, make granules, dry, and granulate to obtain granules.
丸剂这样制备:取油菜蜂花粉破壁后用高速粉碎机粉碎成120目的细粉。其余益母草、萹蓄、红花、知母、黄柏分别加20倍量水煎煮2次,每次2小时,7000rpm离心,合并离心后所得水液,减压浓缩成浸膏,减压干燥;干浸膏粉碎成120目的细粉,加入油菜蜂花粉细粉混合均匀,加入相对密度为1.37的炼蜜与开水,制丸,即得丸剂。The pills are prepared in the following way: the rapeseed bee pollen is broken and crushed into 120-mesh fine powder with a high-speed pulverizer. Add 20 times the amount of water to decoct the remaining motherwort, sage, safflower, Anemarrhena anemarrhena, and Cortex Phellodendri, respectively, twice, each time for 2 hours, and centrifuge at 7000rpm, combine and centrifuge the obtained water, concentrate under reduced pressure to form an extract, and dry under reduced pressure; The dry extract is crushed into 120-mesh fine powder, mixed with rapeseed bee pollen fine powder, added with refined honey and boiled water with a relative density of 1.37, and made into pellets to obtain pills.
根据祖国医学的理论,本发明采用益母草、萹蓄、红花、油菜蜂花粉、知母(盐炒)、黄柏(盐炒)组方。其中益母草活血祛瘀;萹蓄能清下焦湿热,利尿通淋;红花辛散温通,专入血分,能活血祛瘀、通调经脉、止痛;盐炒知母与盐炒黄柏能引药下行,专于入肾,并具有较强的滋阴降火、退虚热的作用。诸药合用,可起到清热利湿,活血散结的功能。另外花粉是前列腺炎的克星,尤以油菜蜂花粉效果最佳,所以本发明中加入油菜蜂花粉,对慢性前列腺炎湿热挟瘀证有较好的疗效。本发明针对现有技术,将油菜蜂花粉破壁后入药,因为花粉外部有一层坚硬的耐酸耐碱且抗生物分解的孢子壁,人体无法直接吸收,将其破壁后可加强对其有效成分的利用,增加生物利用率。与现有技术相比:本发明提供的药物具有疗效好、显效快、且复发率小,不良反应小的特点。对慢性前列腺疾病的治疗临床效果十分显著;本发明提供的药物的制备方法工艺简单、产品质量容易受到控制;特别是本发明中制备各种药品剂型时比较优选的选择了辅料,使得得到的药物制剂质量能够满足国家的相关标准要求。According to the theory of motherland's medicine, the present invention adopts motherwort, sage, safflower, rape bee pollen, Anemarrhena (stir-fried with salt), Phellodendron Phellodendri (stir-fried with salt). Among them, Motherwort promotes blood circulation and removes blood stasis; Leonurus can clear the dampness and heat of the lower body, diuresis and relieve stranguria; safflower pungent dissipates temperature and clears the blood, can activate blood and remove blood stasis, regulate meridians, and relieve pain; The medicine goes down, and it is specially designed to enter the kidney, and has a strong effect of nourishing yin and reducing fire, and reducing asthenic heat. The combination of various medicines can play the functions of clearing away heat and promoting dampness, promoting blood circulation and dispelling stagnation. In addition, pollen is the nemesis of prostatitis, especially rapeseed bee pollen has the best effect, so adding rapeseed bee pollen in the present invention has a good curative effect on chronic prostatitis with damp-heat holding stasis syndrome. Aiming at the prior art, the present invention breaks the wall of rape bee pollen and uses it as medicine, because the outside of the pollen has a hard spore wall that is resistant to acid, alkali and biodegradation, which cannot be directly absorbed by the human body, and its active ingredients can be strengthened after breaking the wall utilization and increase bioavailability. Compared with the prior art: the medicine provided by the invention has the characteristics of good curative effect, rapid effect, low recurrence rate and small adverse reaction. The clinical effect to the treatment of chronic prostatic disease is very remarkable; the preparation method process of the medicine provided by the invention is simple, and the product quality is easy to be controlled; especially when preparing various pharmaceutical dosage forms in the present invention, the auxiliary materials are preferably selected, so that the obtained medicine The quality of preparations can meet the requirements of relevant national standards.
具体实施方式:Detailed ways:
本发明的实施例1:胶囊剂:取益母草750g、萹蓄500g、红花250g、油菜蜂花粉100g、知母(盐炒)150g、黄柏(盐炒)150g,取油菜蜂花粉破壁后用高速粉碎机粉碎成120目的细粉。其余益母草、萹蓄、红花、知母、黄柏分别加水煎煮2次,每次2小时,第一次加12倍量水,第二次加10倍量水,合并水煎液,减压浓缩成50℃时测相对密度为1.33~1.37浸膏,干燥;干浸膏粉碎成80目以上的细粉,加入油菜蜂花粉细粉、淀粉混合均匀,用浓度为85%乙醇制粒,十燥,整粒,充填,即得胶囊。本品口服,一日三次,每次2粒。Embodiment 1 of the present invention: Capsules: get Leonurus 750g, 500g of succulents, 250g of safflower, 100g of rape bee pollen, 150g of Anemarrhena anemarrhena (stir-fried with salt), 150g of Phellodendron Phellodendri (stir-fried with salt), take rape bee pollen and use after breaking the wall High-speed pulverizer crushed into 120 mesh fine powder. The remaining motherwort, sage, safflower, anemarrhena, and Phellodendron cork were decocted twice, each time for 2 hours, adding 12 times the amount of water for the first time, adding 10 times the amount of water for the second time, combining the decoction, and decompressing. When concentrated to 50°C, the measured relative density is 1.33 to 1.37. The extract is dried; the dry extract is crushed into a fine powder of more than 80 meshes, mixed with rapeseed bee pollen fine powder and starch, and granulated with 85% ethanol. Dry, granulate, and fill to obtain capsules. This product is taken orally, three times a day, 2 capsules each time.
本发明的实施例2:片剂:益母草1500g、萹蓄1000g、红花500g、油菜蜂花粉200g、知母(盐炒)300g、黄柏(盐炒)300gEmbodiment 2 of the present invention: Tablet: Leonurus 1500g, Leonurus 1000g, Safflower 500g, Rapeseed bee pollen 200g, Anemarrhena anemarrhena (stir-fried with salt) 300g, Cortex Phellodendri (stir-fried with salt) 300g
取油菜蜂花粉破壁后用高速粉碎机粉碎成80目的细粉。其余益母草、萹蓄、红花、知母、黄柏分别加5倍量水煎煮5次,每次5小时,合并水煎液,减压浓缩成浸膏,减压干燥;干浸膏粉碎成80目的细粉,加入油菜蜂花粉细粉、硬脂酸镁混合均匀,用浓度为75%乙醇制粒,压片,用薄膜包衣辅料对素片进行包衣,即得片剂。Get the rapeseed bee pollen and break the wall and grind it into 80 mesh fine powder with a high-speed pulverizer. The remaining motherwort, succulents, safflower, anemarrhena, and cortex were decocted with 5 times the amount of water for 5 times, 5 hours each time, combined with decoction, concentrated under reduced pressure to obtain extract, and dried under reduced pressure; the dry extract was crushed into The 80-mesh fine powder is added with rapeseed bee pollen fine powder and magnesium stearate, mixed evenly, granulated with 75% ethanol, compressed into tablets, and coated with film coating auxiliary materials to obtain tablets.
本发明的实施例3:颗粒剂:益母草187.5g 萹蓄125g 红花62.5gEmbodiment 3 of the present invention: Granules: motherwort 187.5g, safflower 125g, safflower 62.5g
油菜蜂花粉25g 知母(盐炒)37.5g 黄柏(盐炒)37.5gRapeseed bee pollen 25g Anemarrhena (stir-fried with salt) 37.5g Phellodendron (stir-fried with salt) 37.5g
取油菜蜂花粉破壁后用高速粉碎机粉碎成80目的细粉。其余益母草、萹蓄、红花、知母、黄柏分别加10倍量水煎煮1小时,1000rpm离心,离心后所得水液减压浓缩成浸膏,减压干燥;干浸膏粉碎成80目的细粉,加入油菜蜂花粉,浓度为10%的淀粉浆混合均匀后制成软材,过筛,制颗粒,干燥,整粒,即得颗粒剂。Get the rapeseed bee pollen and break the wall and grind it into 80 mesh fine powder with a high-speed pulverizer. Add 10 times the amount of water to decoct the remaining motherwort, sage, safflower, Anemarrhena anemarrhena, and Cortex Phellodendri respectively for 1 hour, and centrifuge at 1000 rpm. For the fine powder, add rapeseed bee pollen and starch slurry with a concentration of 10% and mix evenly to make a soft material, sieve, make granules, dry, and granulate to obtain granules.
本发明的实施例4:丸剂:益母草750g、萹蓄500g、红花250g、油菜蜂花粉100g、知母(盐炒)150g、黄柏(盐炒)150gEmbodiment 4 of the present invention: Pills: Leonurus 750g, 500g of safflower, 250g of safflower, 100g of rape bee pollen, 150g of Anemarrhena (stir-fried with salt), 150g of Cortex Phellodendri (stir-fried with salt)
取油菜蜂花粉破壁后用高速粉碎机粉碎成120目的细粉。其余益母草、萹蓄、红花、知母、黄柏分别加20倍量水煎煮2次,每次2小时,7000rpm离心,合并离心后所得水液,减压浓缩成浸膏,减压干燥;干浸膏粉碎成120目的细粉,加入油菜蜂花粉细粉混合均匀,加入相对密度为1.37的炼蜜与开水,制丸,即得丸剂。Get the rapeseed bee pollen and break it into a 120-mesh fine powder with a high-speed pulverizer. Add 20 times the amount of water to decoct the remaining motherwort, sage, safflower, Anemarrhena anemarrhena, and Cortex Phellodendri, respectively, twice, each time for 2 hours, and centrifuge at 7000rpm, combine and centrifuge the obtained water, concentrate under reduced pressure to form an extract, and dry under reduced pressure; The dry extract is crushed into 120-mesh fine powder, mixed with rapeseed bee pollen fine powder, added with refined honey and boiled water with a relative density of 1.37, and made into pellets to obtain pills.
为了满足患者需要,本制剂可以制备成其它剂型,如:软胶囊、合剂、滴丸、浓缩丸,甚至是注射制剂;这些剂型具有各自的优点,可以最大限度的供医患双方选择使用;满足不同人群的需要。In order to meet the needs of patients, this preparation can be prepared into other dosage forms, such as: soft capsules, mixtures, dripping pills, concentrated pills, and even injections; these dosage forms have their own advantages and can be used by both doctors and patients to the greatest extent; the needs of different groups of people.
本发明胶囊剂质量控制方法为:Capsule quality control method of the present invention is:
鉴别:取本品粉末,置显微镜下观察:花粉粒淡黄色,椭圆形、类圆形或圆形,萌发孔难察见,少数具有3个萌发孔。Identification: Take the powder of this product and observe under a microscope: the pollen grains are light yellow, oval, sub-circular or round, and the germination holes are difficult to see, and a few have 3 germination holes.
取本品装量差异项下的内容物1g,加乙醇5ml浸泡2小时,滤过,滤液作为供试品溶液,另取盐酸小檗碱对照品,加甲醇制成每1ml含0.1mg的溶液,作为对照品溶液。照薄层色谱法(中国药典2000版一部附录VIB)试验,吸取上述两种溶液各3μl,分别点于同一硅胶G薄层板上,以正丁醇-醋酸-水(4∶1∶1)为展开剂,展开,取出,晾干,置紫外光灯(365nm)下检识。供试品色谱中,在与对照品色谱相应的位置上,显相同的黄色荧光斑点。Take 1g of the content of this product under the item of loading difference, add 5ml of ethanol to soak for 2 hours, filter, and use the filtrate as the test solution, and take another berberine hydrochloride reference substance, add methanol to make a solution containing 0.1mg per 1ml , as a reference solution. According to the thin-layer chromatography (Appendix VIB, Chinese Pharmacopoeia 2000 Edition), 3 μl of each of the above two solutions was drawn, respectively spotted on the same silica gel G thin-layer plate, and mixed with n-butanol-acetic acid-water (4:1:1) ) as the developing agent, develop, take out, dry in the air, and put it under ultraviolet light (365nm) for identification. In the chromatogram of the test product, at the position corresponding to the chromatogram of the reference product, the same yellow fluorescent spots appear.
取本品装量差异项下的内容物5g,加甲醇30ml,超声处理30分钟,滤过,滤液挥去甲醇,加水10ml,加到已处理好的D101大孔吸附树脂柱(直径2.5cm,长28cm)上,用水洗脱至洗液无色,弃去水洗脱液,继用乙醇洗脱,收乙醇洗脱液带色部分80ml,加盐酸8ml,加热回流1小时,用40%氢氧化钠液调节pH至中性,浓缩至约10ml,加水10ml,加甲苯20ml振摇提取,分取甲苯层,蒸干,残渣加甲苯1ml使溶解作为供试品溶液。另取拔葜皂苷元,加甲苯20ml制成每Iml含5mg的溶液,作为对照品溶液。照薄层色谱法(中国药典2000版一部附录VIB)试验,吸取上述两种溶液各5μl,分别点于同一硅胶G薄层板上,以甲苯-丙酮(8.5∶1.5)为展开剂,展开,取出,晾干,喷以5%香草醛硫酸溶液显色,在105℃烘至斑点显色清晰。供试品色谱中,在与对照品色谱相应的位置上,显相同颜色的斑点。Take 5g of the content of this product under the item of loading difference, add 30ml of methanol, ultrasonically treat for 30 minutes, filter, evaporate the filtrate to remove methanol, add 10ml of water, add to the D 101 macroporous adsorption resin column (diameter 2.5cm , length 28cm), eluted with water until the lotion was colorless, discarded the water eluate, continued to elute with ethanol, collected 80ml of the colored part of the ethanol eluate, added 8ml of hydrochloric acid, heated to reflux for 1 hour, and washed with 40% Adjust the pH to neutral with sodium hydroxide solution, concentrate to about 10ml, add 10ml of water, add 20ml of toluene and shake to extract, separate the toluene layer, evaporate to dryness, add 1ml of toluene to the residue to dissolve as the test solution. In addition, pluckengenin was taken, and 20ml of toluene was added to make a solution containing 5mg per 1ml, as a reference substance solution. According to the thin-layer chromatography (Appendix VIB, Chinese Pharmacopoeia 2000 Edition), 5 μl of each of the above two solutions was drawn, respectively spotted on the same silica gel G thin-layer plate, and toluene-acetone (8.5:1.5) was used as the developer to develop , take it out, dry it in the air, spray it with 5% vanillin sulfuric acid solution to develop color, and bake it at 105°C until the spot color develops clearly. In the chromatogram of the test product, there are spots of the same color at the position corresponding to the chromatogram of the reference product.
含量测定:盐酸水苏碱照高效液相色谱法(中国药典2000年版一部附录VID)测定,色谱条件与系统适用性试验用用磺酸基团键合硅胶(SCX)的阳离子交换剂为填充剂;以0.05mol/L磷酸二氢钾-三乙胺(100∶0.1)(以磷酸调pH值至2.3)为流动相;检测波长为192nm。理论塔板数按盐酸水苏碱计算应不低于1500。Determination of content: stachydrine hydrochloride is measured according to high performance liquid chromatography (an appendix VID of Chinese Pharmacopoeia 2000 edition), and the cation exchanger of sulfonic acid group bonded silica gel (SCX) is used as filling for chromatographic conditions and system suitability test agent; use 0.05mol/L potassium dihydrogen phosphate-triethylamine (100:0.1) (adjust the pH value to 2.3 with phosphoric acid) as the mobile phase; the detection wavelength is 192nm. The number of theoretical plates should not be less than 1500 based on the calculation of stachydrine hydrochloride.
对照品溶液的制备,精密称取盐酸水苏碱对照品适量,加甲醇制成每1ml含0.5mg的溶液,即得;For the preparation of the reference substance solution, accurately weigh an appropriate amount of stachydrine hydrochloride reference substance, add methanol to make a solution containing 0.5mg per 1ml, and get final product;
供试品溶液的制备,取本品20粒,倾取内容物,研细,精密称取1.5g,置锥形瓶中,精密加入乙醇50ml,称定重量,超声处理(150W,50kHz)30分钟,取出,放冷,称定重量,用乙醇补足减失的重量,滤过,精密量取续滤液25ml,水浴蒸干,残渣加水20ml使溶解,定量转移至分液漏斗中,用醋酸乙酯提取3次,每次25ml,弃去醋酸乙酯液,水液水浴蒸干,残渣加乙醇10ml使溶解,加于中性氧化铝-活性炭柱上(内径150mm,3g∶1g,100~200目,乙醇湿法上柱,先上氧化铝,再上活性炭),用乙醇洗脱,收集洗脱液100ml,水浴蒸干,残渣加0.05mol/L磷酸溶解并转移至10ml量瓶中,加0.05mol/L磷酸至刻度,摇匀,离心,即得;For the preparation of the test solution, get 20 capsules of this product, pour out the contents, grind finely, and accurately weigh 1.5g, put it in a conical flask, add 50ml of ethanol accurately, weigh it, and ultrasonically process it (150W, 50kHz) for 30 minutes. Minutes, take it out, let it cool, weigh it, make up the lost weight with ethanol, filter, accurately measure 25ml of the subsequent filtrate, evaporate to dryness in a water bath, add 20ml of water to the residue to dissolve, transfer it quantitatively to a separatory funnel, and use ethyl acetate Extract the ester three times, 25ml each time, discard the ethyl acetate solution, evaporate the water to dryness in a water bath, add 10ml of ethanol to the residue to dissolve, and add it to a neutral alumina-activated carbon column (inner diameter 150mm, 3g: 1g, 100-200 purpose, ethanol wet column, first on alumina, then on activated carbon), elute with ethanol, collect eluent 100ml, evaporate to dryness in a water bath, add 0.05mol/L phosphoric acid to dissolve the residue and transfer it to a 10ml measuring bottle, add 0.05mol/L phosphoric acid to the mark, shake well, and centrifuge to obtain;
测定法,分别精密吸取对照品溶液与供试品溶液各20μl,注入液相色谱仪,测定,即得,本品每粒含盐酸水苏碱(C7H13ClNO2)不得少于2.4mg。Determination method, respectively accurately absorb 20 μ l of the reference substance solution and the test solution, inject it into the liquid chromatograph, measure, and obtain that each capsule of this product contains stachydrine hydrochloride (C 7 H 13 ClNO 2 ) not less than 2.4 mg .
临床药效:Clinical efficacy:
一、治疗对象及项目:凡符合CP西医诊断标准及排除病例标准者,均可纳入研究对象范围。患者于治疗前后进行主观症状问诊,包括疼痛或不适症状、尿路症状、性与生殖症状和全身症状等四组症状;前例腺指诊是否异常,异常包括大、小、硬、痛、热、结等六个方面;对综合疗效作对比分析。1. Treatment objects and items: Anyone who meets the diagnostic criteria of Western medicine for CP and the criteria for excluding cases can be included in the scope of research objects. Subjective symptom inquiry before and after treatment, including four groups of symptoms such as pain or discomfort symptoms, urinary tract symptoms, sexual and reproductive symptoms, and systemic symptoms; , knot and other six aspects; comparative analysis of comprehensive curative effect.
二、治疗方法:治疗前查血、尿、大便常规和肝、肾功能,正常者给予本发明药物的水剂,连续用药一个月,复查血、尿、大便常规和肝、肾功能,治疗期间不用其它药物。进行疗效观察研究。Two, treatment method: check blood, urine, stool routine and liver, kidney function before treatment, and normal person is given the aqueous preparation of medicine of the present invention, takes continuous medication for one month, checks blood, urine, stool routine and liver, kidney function, during treatment Without other drugs. Observational research on curative effect was carried out.
三、临床疗效:3. Clinical curative effect:
1、为了便于探讨前本发明对CP症状改善情况,我们从疼痛或不适症状、尿路症状、性与生殖症状和全身症状四个方面进行观察,结果见下表:
从该结果可知,本发明对CP的疼痛或不适症状、尿路症状、性与生殖症状和全身症状有较好的改善作用,对尿路症状疗效尤佳。From the results, it can be seen that the present invention has a better effect on improving the pain or discomfort symptoms, urinary tract symptoms, sexual and reproductive symptoms and systemic symptoms of CP, especially for urinary tract symptoms.
2、前列腺指诊情况:其中痊愈66例、显效37例、好转15例、无效22例、有效率为81.67%。该结果显示,本发明对前列腺局部体征有较好的作用。2. Prostate digital examination: 66 cases were cured, 37 cases were markedly effective, 15 cases were improved, 22 cases were ineffective, and the effective rate was 81.67%. The result shows that the present invention has a better effect on the local signs of the prostate.
3、副作用观察:140例CP患者,服用本发明药物后无明显不适,血、尿、大便常规和肝、肾功能检查均正常。3. Observation of side effects: 140 routine CP patients had no obvious discomfort after taking the medicine of the present invention, and blood, urine, stool routine and liver and kidney function tests were all normal.
4、综合疗效评定:参照疗效评定标准,140例CP患者,治愈64例,占45.71%;显效37例,占26.43%;好转22例,占15.71%;无效17例,占12.14%。总有效率为87.85%。可见本发明对CP具有良好的治疗作用。4. Comprehensive curative effect evaluation: According to the curative effect evaluation standard, among 140 CP patients, 64 cases were cured, accounting for 45.71%; 37 cases were markedly effective, accounting for 26.43%; 22 cases were improved, accounting for 15.71%; 17 cases were ineffective, accounting for 12.14%. The total effective rate is 87.85%. It can be seen that the present invention has a good therapeutic effect on CP.
实验:辅料筛选Experiment: excipient screening
在制备过程中,加入的辅料是否得当直接影响制剂的质量和临床应用效果,所以申请人进行了一系列实验以获得最佳的工艺。During the preparation process, whether the added auxiliary materials are appropriate directly affects the quality of the preparation and the effect of clinical application, so the applicant conducted a series of experiments to obtain the best process.
休止角测定采用倾斜箱法:于矩形盒内装满细粉,其松实程度适宜,将盒逐步倾斜至微粉开始流出为止。盒子倾斜的角度即为休止角。若结果大于45%流动性差,易松散。Angle of repose is measured using the tilting box method: fill a rectangular box with fine powder, the degree of looseness is appropriate, and gradually tilt the box until the fine powder starts to flow out. The angle at which the box is tilted is the angle of repose. If the result is greater than 45%, the fluidity is poor and easy to loose.
吸湿性实验:取供试品,约2g,置称量瓶中,精密称定,将称量瓶盖打开,分别放入相对湿度为92%的环境中,于25℃恒温培养箱内放置84小时,取出称量瓶,加盖后精密称定,计算吸湿百分率。结果数值越低说明不易吸湿。Hygroscopicity test: take the test product, about 2g, put it in a weighing bottle, weigh it accurately, open the cap of the weighing bottle, put it into an environment with a relative humidity of 92%, and place it in a constant temperature incubator at 25°C for 84 hour, take out the weighing bottle, accurately weigh after capping, and calculate the percentage of moisture absorption. The lower the value of the result, the less hygroscopic it is.
崩解时限检查:采用转篮法,升降式崩解仪,片剂取6片,胶囊剂取6粒,观察30分钟内通过筛网的情况。丸剂取得丸,观察60分钟内通过筛网的情况。通过率高则崩解性好,更宜人体吸收。
通过辅料筛选实验,采用本发明选择的辅料所制成的制剂,质量稳定,产品质量可控,成型性好。Through the auxiliary material screening experiment, the preparation made by using the selected auxiliary material in the present invention has stable quality, controllable product quality and good formability.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100546933A CN1313079C (en) | 2004-03-17 | 2005-03-16 | Traditional Chinese medicine preparation for treating prostatitis and preparation method thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410022078 CN1562189A (en) | 2004-03-17 | 2004-03-17 | Chinese materia medica preparation for treating prostatitis and preparation technique |
CN200410022078.X | 2004-03-17 | ||
CNB2005100546933A CN1313079C (en) | 2004-03-17 | 2005-03-16 | Traditional Chinese medicine preparation for treating prostatitis and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1689635A CN1689635A (en) | 2005-11-02 |
CN1313079C true CN1313079C (en) | 2007-05-02 |
Family
ID=35345589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100546933A Expired - Lifetime CN1313079C (en) | 2004-03-17 | 2005-03-16 | Traditional Chinese medicine preparation for treating prostatitis and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1313079C (en) |
-
2005
- 2005-03-16 CN CNB2005100546933A patent/CN1313079C/en not_active Expired - Lifetime
Non-Patent Citations (1)
Title |
---|
国家食品药品监督管理局,国家药品标准,新药转正标准 国家药典委员会 编,8.9,国家药典委员会 2003 * |
Also Published As
Publication number | Publication date |
---|---|
CN1689635A (en) | 2005-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103784664B (en) | A kind of prevent and treat biphasic capsule of chronic pelvic inflammatory disease and preparation method thereof and detection method | |
CN111358839B (en) | Formula granules of polygonum capitatum and preparation method thereof | |
CN102397342B (en) | Golden buckwheat rhizome extract, pharmaceutical preparation containing golden buckwheat rhizome extract and preparation method thereof | |
CN103028065B (en) | Preparation containing herba violae, rhizoma cyperi and herba leonuri and preparation method and detection method thereof | |
CN102145106A (en) | Chinese medical composition for treating osteoporosis and granular formulation capable of tonifying kidney and invigorating blood circulation | |
CN102379885B (en) | Pseudo-ginseng triol saponin enteric pellet and capsule and preparation method thereof | |
CN104815025A (en) | Preparation process and quality control method of cassia twig poria cocos preparation | |
CN102349877A (en) | Hydroxychloroquine sulfate capsule, hydroxychloroquine sulfate dispersible tablet and application thereof | |
CN102755369B (en) | Traditional Chinese medicine composition used for treating oral diseases, preparation process thereof, and quality detection method thereof | |
CN101653491A (en) | Preparation technology and quality control method of preparation containing cassia twig and tuckahoe | |
CN104998071A (en) | Compound preparation ofherb of dense flower Bulbophyllum and preparation and detection method for said compound preparation | |
CN1981852A (en) | Tall gastrodia tuber preparation with resuscitation-inducing function, its making and quality controlling method | |
CN101108230B (en) | Di'ao xinxuekang slow release formulated product and method of preparing the same and use thereof | |
CN101411735A (en) | Quality control method of pharmaceutical composition for preventing and treating coronary heart disease | |
CN101647993A (en) | Medicament for treating flu and preparation and detection method thereof | |
CN1313079C (en) | Traditional Chinese medicine preparation for treating prostatitis and preparation method thereof | |
CN102048929B (en) | Xiaoyukang tablet and preparation method thereof | |
CN1803180A (en) | Medicine composition and its preparation method and quality control method | |
CN103285283A (en) | Chinese medicine dispersible tablet for treating breast hyperplasia disease and preparation method as well as quality detection method thereof | |
CN100358492C (en) | Preparation of Chinese traditional medicine for curing headache and preparation method | |
CN106728651A (en) | The preparation method and its method of quality control of a kind of rhizoma cyperi SIWU KELI | |
CN1698757A (en) | Pharmaceutical preparation for treating upper respiratory tract infection and its preparation process and quality control method | |
CN100391491C (en) | A kind of pharmaceutical composition for treating cardiovascular disease and its preparation method | |
CN1220513C (en) | Proprietury Chinese medicine for stopping blood, analgesia, removing blood stasis and engender new and its preparation method | |
CN100487450C (en) | Preparation medicine of wind dispelling pain eliminating tablet and its preparation methid, quality control method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GUIZHOU BAILING GROUP PHARMACY CO., LTD. Free format text: FORMER OWNER: QIYUANYIDE MEDICINES INST., BEIJING Effective date: 20100806 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100070 ROOM 317, LIFE SCIENCES INCUBATOR CENTER, NO.8, HANGFENG ROAD, FENGTAI SCIENCE CITY, FENGTAI DISTRICT, BEIJING CITY TO: 561000 XIHANG AVENUE, ANSHUN ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE, GUIZHOU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100806 Address after: 561000 west of Guizhou Province, Anshun economic and Technological Development Zone Avenue Patentee after: GUIZHOU BAILING ENTERPRISE GROUP PARMACEUTIAL Co.,Ltd. Address before: 100070 room 317 of life science incubation center, 8 Feng Feng Road, Fengtai Science City, Beijing, Fengtai District Patentee before: Beijing Qi Yuan Yi De Pharmaceuticals Research Center |
|
CX01 | Expiry of patent term |
Granted publication date: 20070502 |